The global allogeneic cell therapy market size was exhibited at USD 301.19 million in 2022 and is projected to hit around USD 3,395.28 million by 2032, growing at a CAGR of 27.41% during the forecast period 2023 to 2032.
Key Pointers:
Allogeneic Cell Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 383.75 million |
| Market Size by 2032 | USD 3,395.28 million |
| Growth Rate From 2023 to 2032 | CAGR of 27.41% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Therapy type, Therapeutic area |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled |
SSM Cardinal Glennon Children's Medical Center; Cleveland Cord Blood Center; Duke University School of Medicine; New York Blood Center; Clinimmune Labs; University of Colorado Cord Blood Bank; MD Anderson Cord Blood Bank; LifeSouth Community Blood Centers, Inc.; Bloodworks Northwest; JCR Pharmaceuticals Co., Ltd.; Sumitomo Pharma Co., Ltd.; Atara Biotherapeutics; Mallinckrodt Pharmaceuticals; Tego Science Inc; Takeda Pharmaceutical Company Limited; STEMPEUTICS RESEARCH PVT LTD; Biosolution Co., Ltd.; MEDIPOST Co., Ltd.
|
Allogeneic cell therapy involves transferring cells from healthy donors to patients to treat chronic diseases such as cancer and cardiovascular diseases. The donor cells can be directly administered to genetically similar patients or added to a cell bank.
The therapies are typically produced in large batches from different donor tissues like bone marrow, and the manufacturing process is similar to that used for protein drugs and other large-scale derived materials. Allogeneic cell therapies offer several benefits over autologous therapies, including being less expensive and their availability as a scalable off-the-shelf product. As a result, the adoption of such therapies is increasing with several biotechnology companies conducting clinical trials treatment of various diseases.
There has been a significant increase in the number of allogeneic cell-based therapy clinical trials in recent years. According to the US National Institutes of Health, the number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years, with 1014 MSC-based clinical trials registered in the government database as either completed or in the process as of July 14th, 2021. This growth in clinical trials, combined with advancements in precision medicine and increased cell therapy production facilities is expected to drive market growth in the coming years.
The rising number of regulatory approvals for allogeneic cell-based therapies is expected to boost market growth over the forecast period. For instance, in October 2021, Enzyvant was granted FDA approval for its RETHYMIC, a single-dose regenerative tissue-based therapy for immunological reconstitution in pediatric patients with congenital athymia.
Moreover, in August 2022, Charles River Laboratories received approval from the European Medicines Agency (EMA) for its Memphis cell therapy manufacturing facility, which will enable the commercial production of allogeneic cell therapy. This approval is another significant milestone for the market, as it opens up new possibilities for treating various chronic diseases.
The COVID-19 pandemic had an unfavorable impact on the allogeneic stem cell therapy industry, causing a decline in research and development activities. This has disrupted various processes, including research, clinical trials, manufacturing, and logistics, ultimately affecting the quality of clinical evidence for cell and gene therapies. As a result, evaluating the treatment benefits and economic impacts of these therapies has become more challenging.
However, the pandemic has also raised awareness about the use of cell therapy as a potential treatment option for COVID-19. This increasing awareness is expected to have a positive impact on the market in the coming years. For instance, in May 2020, Lineage Cell Therapeutics received USD 5 million in emergency funding from the California Institute for Regenerative Medicine (CIRM) to develop a potential vaccine against SARS-CoV-2 using VAC, their allogeneic dendritic cell therapy.
The key players in the market are implementing several strategic initiatives to develop novel offerings. For instance, in February 2022, ONK Therapeutics entered into a collaboration with Intellia Therapeutics to develop five allogeneic NK cell therapies using Intellia's genome editing platform. This strategic partnership is expected to accelerate the development of novel therapies and contribute to high market growth.
Some of the prominent players in the Allogeneic Cell Therapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Allogeneic Cell Therapy market.
By Therapy Type
By Therapeutic Area
By Region
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising prevalence of chronic and infectious diseases
3.3.1.2. Increasing FDA approvals of allogeneic cell therapies
3.3.1.3. Increasing government funding for stem cell therapies
3.3.2. Market Restraint Analysis
3.3.2.1. High research costs and challenges with immune rejection
3.4. Industry Analysis Tools
3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.4.2. Porter's Five Forces Analysis
3.4.3. Penetration and Growth Prospect Mapping, 2022
3.5. Pipeline Analysis
3.6. COVID-19 Impact Analysis
Chapter 4. Allogeneic Cell Therapy Market: Therapy Type Business Analysis
4.1. Allogeneic Cell Therapy Market: Therapy Type Market Share Analysis
4.2. Allogeneic Cell Therapy Market Estimates & Forecast, By Therapy Type
4.3. Stem Cell Therapies
4.3.1. Global Stem Cell Therapies Market, 2020 - 2032
4.3.2. Hematopoietic Stem Cell Therapies
4.3.2.1. Global Hematopoietic Stem Cell Therapies Market, 2020 - 2032
4.3.3. Mesenchymal Stem Cell Therapies
4.3.3.1. Global Mesenchymal Stem Cell Therapies Market, 2020 - 2032
4.4. Non-stem Cell Therapies
4.4.1. Global Non-stem Cell Therapies Market, 2020 - 2032
4.4.2. Keratinocytes & Fibroblast-based Therapies
4.4.2.1. Global Keratinocytes & Fibroblast-based Therapies Market, 2020 - 2032
4.4.3. Other Non-stem Cell Therapies
4.4.3.1. Global Other Non-stem Cell Therapies Market, 2020 - 2032
Chapter 5. Allogeneic Cell Therapy Market: Therapeutic Area Business Analysis
5.1. Allogeneic Cell Therapy Market: Therapeutic Area Market Share Analysis
5.2. Allogeneic Cell Therapy Market Estimates & Forecast, By Therapeutic Area
5.3. Hematological Disorders
5.3.1. Global Haematological Disorders Market, 2020 - 2032
5.4. Dermatological Disorders
5.4.1. Global Dermatological Disorders Market, 2020 - 2032
5.5. Others
5.5.1. Global Other Therapeutic Areas Market, 2020 - 2032
Chapter 6. Allogeneic Cell Therapy Market: Regional Business Analysis
6.1. Allogeneic Cell Therapy Market Share By Region, 2022 & 2032
6.2. North America
6.2.1. North America Allogeneic Cell Therapy Market, 2020 - 2032
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. Regulatory Framework
6.2.2.5. Reimbursement Scenario
6.2.2.6. U.S. Allogeneic Cell Therapy Market, 2020 - 2032
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Canada Allogeneic Cell Therapy Market, 2020 - 2032
6.3. Europe
6.3.1. Europe Allogeneic Cell Therapy Market, 2020 - 2032
6.3.2. U.K.
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. Regulatory Framework
6.3.2.5. Reimbursement Scenario
6.3.2.6. U.K. Allogeneic Cell Therapy Market, 2020 - 2032
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Allogeneic Cell Therapy Market, 2020 - 2032
6.3.4. Switzerland
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. Switzerland Allogeneic Cell Therapy Market, 2020 - 2032
6.4. Asia Pacific
6.4.1. Asia Pacific Allogeneic Cell Therapy Market, 2020 - 2032
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. Regulatory Framework
6.4.2.5. Reimbursement Scenario
6.4.2.6. Japan Allogeneic Cell Therapy Market, 2020 - 2032
6.4.3. India
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. India Allogeneic Cell Therapy Market, 2020 - 2032
6.4.4. South Korea
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. South Korea Allogeneic Cell Therapy Market, 2020 - 2032
6.5. Rest of the World
6.5.1. Rest of the World Allogeneic Cell Therapy Market, 2020 - 2032
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Profiles/Listing
7.3.1. SSM Cardinal Glennon Children's Medical Center
7.3.1.1. Overview
7.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Cleveland Cord Blood Center
7.3.2.1. Overview
7.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Duke University School of Medicine
7.3.3.1. Overview
7.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. New York Blood Center
7.3.4.1. Overview
7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Clinimmune Labs, University of Colorado Cord Blood Bank
7.3.5.1. Overview
7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. MD Anderson Cord Blood Bank
7.3.6.1. Overview
7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. LifeSouth Community Blood Centers, Inc.
7.3.7.1. Overview
7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Bloodworks Northwest
7.3.8.1. Overview
7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.8.3. Product Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. JCR Pharmaceuticals Co., Ltd.
7.3.9.1. Overview
7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.9.3. Product Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Sumitomo Pharma Co., Ltd.
7.3.10.1. Overview
7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.10.3. Product Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Atara Biotherapeutics
7.3.11.1. Overview
7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.11.3. Product Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. Mallinckrodt Pharmaceuticals
7.3.12.1. Overview
7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.12.3. Product Benchmarking
7.3.12.4. Strategic Initiatives
7.3.13. Tego Science Inc.
7.3.13.1. Overview
7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.13.3. Product Benchmarking
7.3.13.4. Strategic Initiatives
7.3.14. Takeda Pharmaceutical Company Limited.
7.3.14.1. Overview
7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.14.3. Product Benchmarking
7.3.14.4. Strategic Initiatives
7.3.15. STEMPEUTICS RESEARCH PVT LTD.
7.3.15.1. Overview
7.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.15.3. Product Benchmarking
7.3.15.4. Strategic Initiatives
7.3.16. Biosolution Co., Ltd.
7.3.16.1. Overview
7.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.16.3. Product Benchmarking
7.3.16.4. Strategic Initiatives
7.3.17. MEDIPOST Co., Ltd.
7.3.17.1. Overview
7.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.17.3. Product Benchmarking
7.3.17.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers